Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges.
about
Update on CD40 and CD154 blockade in transplant modelsAutoimmune therapies targeting costimulation and emerging trends in multivalent therapeuticsA Short History of the B-Cell-Associated Surface Molecule CD40A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors.Galectin-9 controls CD40 signaling through a Tim-3 independent mechanism and redirects the cytokine profile of pathogenic T cells in autoimmunity.Multifunctional CD40L: pro- and anti-neoplastic activity.Excess soluble CD40L contributes to blood brain barrier permeability in vivo: implications for HIV-associated neurocognitive disordersDifferential TRAF3 utilization by a variant human CD40 receptor with enhanced signalingMultipotent mesenchymal stromal cells synergize with costimulation blockade in the inhibition of immune responses and the induction of Foxp3+ regulatory T cells.Ligation of CD40 receptor in human B lymphocytes triggers the 5-lipoxygenase pathway to produce reactive oxygen species and activate p38 MAPK.Fibronectin type III domains engineered to bind CD40L: cloning, expression, purification, crystallization and preliminary X-ray diffraction analysis of two complexesThe effect of glatiramer acetate therapy on functional properties of B cells from patients with relapsing-remitting multiple sclerosis.A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantationIntratumoral delivery of CD154 homolog (Ad-ISF35) induces tumor regression: analysis of vector biodistribution, persistence and gene expressionExpression, purification and biological characterization of the extracellular domain of CD40 from Pichia pastorisApoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagementAdvances in pharmacotherapy for primary biliary cirrhosis.Current and future immunomodulation strategies to restore tolerance in autoimmune diseases.Clinical targeting of the TNF and TNFR superfamiliesDifferential modulation by delta9-tetrahydrocannabinol (∆9)-THC) of CD40 ligand (CD40L) expression in activated mouse splenic CD4+ T cellsSymmetry Controlled, Genetic Presentation of Bioactive Proteins on the P22 Virus-like Particle Using an External Decoration Protein.CD40 and autoimmunity: the dark side of a great activator.Immunobiology of transplantation: impact on targets for large and small molecules.The use of agonistic anti-CD40 therapy in treatments for cancer.B-cell targeted therapeutics in clinical development.Novel insights into anti-CD40/CD154 immunotherapy in transplant tolerance.Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases.Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect.RNAi-mediated CD40-CD154 interruption promotes tolerance in autoimmune arthritis.Regulatory role of CD40 in obesity-induced insulin resistance.New frontiers for platelet CD154.The Role of Costimulation Blockade in Solid Organ and Islet Xenotransplantation.Targeting autoreactive germinal centers to curb autoimmunity.Anti-CD40 antibody-mediated costimulation blockade promotes long-term survival of deep-lamellar porcine corneal grafts in non-human primates.Fc-Silent Anti-CD154 Domain Antibody Effectively Prevents Nonhuman Primate Renal Allograft Rejection.Müller Cell-Microglia Cross Talk Drives Neuroinflammation in Diabetic Retinopathy.
P2860
Q26798362-51814306-CEB4-4041-88B1-D9E99FB9C6BCQ26823789-2C43B07F-82E3-4921-9776-F66AABE7ECBFQ27007137-215EAFB7-65CA-4A15-A0DD-DF27B2BB843CQ33415880-1DF40776-675D-4D12-9FC6-3B6085F9AD8DQ34299740-83E54226-53CB-49FB-B2FA-AABE0E4CDDDFQ34422566-8974207F-8D8F-48C9-836A-7B5684423DB7Q34517239-DDB17F69-C1AE-4EA9-8022-59774714E4C8Q34580224-6C1CA7CE-692D-4B48-9153-611B3CB2ED57Q34601883-339FD3D6-CBFC-4B9C-9580-A0C9EEFEAD18Q34616959-AE01BE98-345C-4C48-B9DD-C7D2C6DFA571Q34976775-7463A647-ABE6-4E43-A3D7-C5BA684F3956Q35105313-E64D2B87-4C0F-419F-9F6E-04B2010C4A08Q35379384-C80BCC5D-88ED-4A86-A0F2-E228F419AB0AQ35800342-D21B00D5-7663-4367-954D-1A52830AEAD4Q35904275-AD9495B5-93EC-483B-BA2C-1C105B72B0D0Q36079365-A853925F-8366-4E4D-B34F-4AFFD417178BQ36116022-11AE78BA-AF72-45A4-87CA-727E8B464456Q36506677-4C1CDCC7-FA68-40E5-A8C1-4BF9D4408A5BQ36762882-3B5CF4AE-F11C-4338-BEF5-12ECF8DB9B26Q36854921-E15C0343-5E19-430B-9487-5290E0D0AD1FQ36892485-AABF6CB0-1B30-45FF-9710-0081A76C9883Q37365433-5F35F8FB-DDCC-487B-BAA8-ACFC9EB878D4Q37895906-C0762DFD-69EF-4FCE-AC3B-153A7D4C5F53Q38026924-F8BF5C4E-493B-4E3F-9405-4C167D196067Q38097162-83F22D6D-155E-405D-95CF-726299F6C17EQ38445344-56823044-B226-4097-B16A-61F963FB6256Q38748557-FDBFB91C-4497-4DF8-AE58-1836B9745BA9Q39409268-854E2BD8-1B2A-41B6-9DA0-90D599E8C40BQ40726435-6B60C6D6-E1B8-4CAF-8F47-EE4C56915AF1Q41179559-10A2EB52-5334-4704-AF8B-C27AA9184328Q43182095-E13AF802-71DC-4F35-A224-A9D48B1F182CQ44770974-4D1465CB-7073-41ED-9243-E1F8688F519AQ47111355-6C049322-CEB0-4F5B-8935-4004AEDFB6E4Q48298408-EB10FAF6-A39C-46E2-B6C0-0C1EC0677F36Q50948280-B9B4A33E-3071-4173-83B0-86729222B0D4Q53932141-9402AC4E-4ABE-4E24-8D8B-DE521DEF6A5C
P2860
Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Therapeutic interventions targ ...... opportunities and challenges.
@ast
Therapeutic interventions targ ...... opportunities and challenges.
@en
type
label
Therapeutic interventions targ ...... opportunities and challenges.
@ast
Therapeutic interventions targ ...... opportunities and challenges.
@en
prefLabel
Therapeutic interventions targ ...... opportunities and challenges.
@ast
Therapeutic interventions targ ...... opportunities and challenges.
@en
P1476
Therapeutic interventions targ ...... opportunities and challenges.
@en
P2093
Che-Leung Law
Iqbal S Grewal
P356
10.1007/978-0-387-89520-8_2
P407
P577
2009-01-01T00:00:00Z